John L. Brottem Net Worth

The estimated Net Worth of John L. Brottem is at least $1.13 Milione dollars as of 15 August 2024. Mr Brottem owns over 3,011 units of Outset Medical stock worth over $117,450 and over the last 4 years he sold OM stock worth over $1,010,596.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Brottem OM stock SEC Form 4 insiders trading

Mr has made over 41 trades of the Outset Medical stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 3,011 units of OM stock worth $2,529 on 15 August 2024.

The largest trade he's ever made was exercising 12,761 units of Outset Medical stock on 30 November 2022 worth over $120,974. On average, Mr trades about 3,532 units every 35 days since 2020. As of 15 August 2024 he still owns at least 230,295 units of Outset Medical stock.

You can see the complete history of Mr Brottem stock trades at the bottom of the page.

Mr. John L. Brottem biography

John L. Brottem is the Gen. Counsel & Sec. at Outset Medical.

How old is Mr Brottem?

Mr Brottem is 47, he's been the Gen. Counsel & Sec. of Outset Medical since . There are 6 older and 3 younger executives at Outset Medical. The oldest executive at Outset Medical, Inc. is Donald Siemens, 70, who is the Independent Director.

Insiders trading at Outset Medical

Over the last 4 years, insiders at Outset Medical have traded over $829,589,795 worth of Outset Medical stock and bought 42,000 units worth $1,172,030 . The most active insiders traders include Pincus Llc Warburg, Pincus X, L.P.Warburg Pincu... e Pincus X, L.P.Wp X Finance,.... On average, Outset Medical executives and independent directors trade stock every 7 days with the average trade being worth of $44,055. The most recent stock trade was executed by Leslie Trigg on 15 August 2024, trading 5,308 units of OM stock currently worth $4,459.

What does Outset Medical do?

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Complete history of Mr Brottem stock trades at Outset Medical

Outset Medical executives and stock owners

Outset Medical executives and other stock owners filed with the SEC include:

• Leslie L. Trigg,
  Pres, CEO & Director
• Martin Vazquez,
  Chief Operating Officer
• Nabeel Ahmed,
  CFO, Principal Financial Officer & Principal Accounting Officer
• Jean-Olivier Racine,
  Chief Technology Officer
• Steven S. Williamson,
  Chief Commercial Officer
• Jeffrey Hussey,
  President, Chief Operating Officer, Director
• Robin Adair,
  Vice President - Exploration
• Paul Dumas,
  Executive Vice President - Finance, Director
• Anthony Glavac,
  Chief Financial Officer
• Robert Wares,
  Executive Chairman of the Board, Chief Executive Officer
• Cathy Singer,
  Independent Director
• Donald Siemens,
  Independent Director
• Amy Satov,
  Independent Director
• Luc Lessard,
  Independent Director
• John Burzynski,
  Independent Director
• Lili Mance,
  Corporate Secretary
• Killian Charles,
  Vice President - Corporate Development
• James S. Mazzola,
  Head of Investor Relations
• Tonya Saffer,
  Head of Gov. Affairs & Market Access
• Dr. Michael Aragon M.D.,
  Chief Medical Officer
• Stacey L. Porter,
  Chief People Officer
• Nicole Shannon,
  Director of Marketing Communications
• John L. Brottem,
  Gen. Counsel & Sec.
• Brent D. Lang,
  Director
• Pincus X, L.P.Warburg Pincu...,
  
• Pincus Llc Warburg,
  
• Martin Vazquez,
  Chief Operating Officer
• Catherine M. Szyman,
  Director
• Pincus X, L.P.Warburg Pincu...,
  
• Pincus X, L.P.Warburg Pincu...,
  
• Pincus X, L.P.Wp X Finance,...,
  
• Rebecca Chambers,
  Chief Financial Officer
• Leslie Trigg,
  Chair and CEO
• D Keith Grossman,
  Director
• Jean Olivier Racine,
  Chief Technology Officer
• Karen Drexler,
  Director
• Patrick T Hackett,
  Director
• James F. Hinrichs,
  Director
• Stacey L. Porter,
  Chief People Officer
• Dale E Jones,
  Director
• Nabeel Ahmed,
  Chief Financial Officer
• Steven S. Williamson,
  Chief Commercial Officer
• John L. Brottem,
  General Counsel
• Marc Nash,
  SVP Operations and R&D